Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Basic Science, biomarkers, new diagnostics and translational research

783 - Crizotinib could overcome acquired resistance to alectinib caused by HGF autocrine in ALK rearranged non-small cell lung cancer


21 Dec 2015


Basic Science, biomarkers, new diagnostics and translational research


Hideko Isozaki


Annals of Oncology (2015) 26 (suppl_9): 1-7. 10.1093/annonc/mdv517


H. Isozaki1, E. Ichihara2, N. Takigawa3, K. Ohashi4, N. Ochi3, M. Yasugi5, T. Ninomiya4, H. Yamane3, D. Minami4, T. Kubo4, A. Sato4, K. Hotta4, K. Sakai6, K. Matsumoto6, S. Hosokawa7, A. Bessho7, T. Sendo1, M. Tanimoto5, K. Kiura4

Author affiliations

  • 1 Department Of Clinical Pharmaceutics, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 700-8558 - Okayama/JP
  • 2 Department Of Hematology/oncology, Vanderbilt Ingram Cancer Center, Nashville/US
  • 3 Department Of General Internal Medicine 4, Kawasaki Medical School,Kawasaki Hospital, Okayama/JP
  • 4 Department Of Respiratory Medicine, Okayama University Hospital, 700-8558 - Okayama/JP
  • 5 Department Of Hematology, Oncology And Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 700-8558 - Okayama/JP
  • 6 Division Of Tumor Dynamics And Regulation, Cancer Research Institute, Kanazawa University, Kanazawa/JP
  • 7 Department Of Respiratory Medicine, Japanese Red Cross Okayama Hospital, 700-0491 - Okayama/JP

Abstract 783


The second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) alectinib demonstrated promising efficacy with a durable response rate (objective response rate,: 93.5%; 95% CI, 82.1–98.6) and a favorable toxic profile in patients with ALK-rearranged advanced non-small cell lung cancer in a clinical phase II study. This reagent could also overcome acquired resistance to the first-generation ALK TKI crizotinib. Two randomized phase III studies comparing alectinib with crizotinib in treatment-naïve ALK-positive advanced lung cancer are currently ongoing. However, even for this promising agent, as well as for other TKIs, acquired resistance is a major limitation of its efficacy. In order to overcome acquired resistance to alectinib, we investigated the mechanisms of resistance.


We established an alectinib-resistant cell line, ABC-11/CHR, by continuous exposure to alectinib, from our original cell line ABC-11 (EML4-ALK variant 3b E6; A20), which was derived from the pleural effusion of a treatment-naïve patient. Using these cell lines, we determined the mechanisms of resistance to alectinib.


ABC-11/CHR was 40-fold more resistant to alectinib than the parental ABC-11. MET was activated in ABC-11/CHR as a result of autocrine hepatocyte growth factor (HGF) signaling. An anti-HGF antibody or a selective MET inhibitor SGX523 effectively inhibited growth when combined with alectinib. In addition, crizotinib, which targets both ALK and MET, inhibited the growth both in vitro and in vivo. Finally, in order to determine if our observations are clinically relevant, we investigated a pair of tissue specimens obtained from a patient pre- and post-alectinib. Immunostaining showed HGF overexpression in the post-alectinib specimen, but not in the pre-alectinib specimen.


We found that HGF autocrine caused acquired resistance to alectinib in the preclinical model and that crizotinib could overcome the resistance. Furthermore, HGF-induced acquired resistance was clinically relevant. Based on these observations, we have started a phase II clinical trial validating the efficacy of crizotinib in alectinib-refractory patients (UMIN registration number 000015984).

Clinical trial identification


N. Takigawa: Boehringer Ingelheim, Chugai Pharma, Pfizer, Sanofi, AstraZeneca, Taiho Pharmaceutical, Kyowa-Hakko Kirin Lilly Nipponkayaku Nihon Shinyaku Taisho Toyama. K. Hotta: Honoraria from Speakers Bureau 1, Taiho Pharmaceutical 2, Lilly 3, Daiichi-Sankyo 4, Pfizer 5, Nipponkayaku 6, Boehringer Ingelheim 7, Chugai Pharma 8, AstraZeneca 9, Sanofi 10, MSD. K. Kiura: Chugai Pharma Pfizer Novartis Pharma. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings